Short Interest in Jaguar Animal Health, Inc. (NASDAQ:JAGX) Expands By 106.8%

Jaguar Animal Health, Inc. (NASDAQ:JAGX) was the target of a large increase in short interest in August. As of August 31st, there was short interest totaling 242,001 shares, an increase of 106.8% from the August 15th total of 117,037 shares. Approximately 4.7% of the shares of the stock are sold short. Based on an average daily volume of 151,797 shares, the days-to-cover ratio is presently 1.6 days.

Jaguar Animal Health Stock Up 1.9%

Shares of JAGX stock traded up $0.01 on Monday, hitting $0.32. The stock had a trading volume of 434,972 shares, compared to its average volume of 138,995. The company has a quick ratio of 0.40, a current ratio of 0.69 and a debt-to-equity ratio of 0.35. The business has a 50 day moving average price of $1.12 and a 200 day moving average price of $6.81. Jaguar Animal Health has a one year low of $0.29 and a one year high of $85.40. The company has a market cap of $1.65 million, a PE ratio of -0.00 and a beta of -0.07.

Jaguar Animal Health (NASDAQ:JAGX) last issued its quarterly earnings data on Wednesday, August 19th. The biotechnology company reported ($15.70) earnings per share (EPS) for the quarter, beating the consensus estimate of ($52.15) by $36.45. The business had revenue of $1.23 million for the quarter, compared to analysts’ expectations of $4.24 million.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on JAGX shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Jaguar Animal Health in a report on Friday, July 17th. Wall Street Zen raised Jaguar Animal Health from a “sell” rating to a “hold” rating in a research note on Saturday, May 23rd. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company has an average rating of “Sell”.

About Jaguar Animal Health

Jaguar Animal Health, Inc is a biopharmaceutical company focused on the development and commercialization of novel therapeutics for the gastrointestinal health of food-producing animals, with an emphasis on swine and poultry. The company’s research and development efforts target common enteric disorders such as post-weaning diarrhea in pigs and clostridial overgrowth in broiler chickens, aiming to provide effective alternatives to traditional antibiotic treatments.

Jaguar Animal Health was formed in early 2019 through the acquisition of the animal health business of Aratana Therapeutics by Actinium Animal Health, followed by a corporate rebranding.